Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients

Key facts

Sponsor

Power Life Sciences Inc.

Principal Investigator

Michael B Gill

Power Life Sciences Inc.

Enrollment

500 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic hairy cell leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06965114
  Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
  National Cancer Institute (NCI)
• RECRUITINGNANCT06781515
  Assessment of Disease Burden in Hairy Cell Leukemia
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• RECRUITINGPHASE2NCT06311227
  Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
  National Cancer Institute (NCI)
• RECRUITINGNCT06774677
  Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• RECRUITINGNCT06764524
  Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• RECRUITINGPHASE2NCT06561360
  A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE1NCT06340737
  AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
  Stanford University
• RECRUITINGPHASE1NCT04815356
  Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
  National Cancer Institute (NCI)

See all trials for Classic hairy cell leukemia →